Core Insights - Kestra Medical Technologies, Ltd. is participating in the American Heart Association (AHA) Scientific Sessions 2025, highlighting its commitment to advancing cardiac care through innovative technology [1] - The company will present primary results from the ACE-PAS Trial, which evaluates a next-generation wearable cardioverter defibrillator system, emphasizing its significance in real-world clinical applications [2][3] Company Overview - Kestra Medical Technologies focuses on wearable medical devices and digital healthcare, aiming to improve patient outcomes in cardiovascular disease through connected monitoring and therapeutic interventions [6] Study Details - The ACE-PAS Trial is the largest prospective study of its kind, enrolling over 20,000 patients in the U.S. to assess the effectiveness and safety of the wearable cardioverter defibrillator [3] - Key endpoints of the study include overall shock conversion success, inappropriate shock rate, first shock conversion success, median daily wear time, and false alarm rate [3] Industry Impact - The selection of the ACE-PAS study for a late-breaking presentation at AHA underscores the growing recognition of wearable defibrillator therapy and its role in enhancing clinical insights for cardiac recovery [4] - Kestra's innovations are positioned to redefine the integration of wearable monitoring and therapy within connected care and digital health, aiming to optimize patient protection and recovery [4] Event Participation - At the AHA conference, Kestra will also host live demonstrations and discussions, showcasing its leadership in data-driven solutions for cardiac recovery [5]